Back

Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough: Chairpersons conclusion

3 March 2018 (14:40 - 14:45)
Organised by:
Congress Presentation Part of: Controversies on anticoagulants post-MI antithrombotic treatment Acute Coronary Syndromes: Post-Infarction Period ACVC Premium Access Acute Cardiovascular Care 2018

9 More presentations in this session

Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - PRO.
Doctor A. Rubboli (Ravenna, IT)
Slides Video
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - CONTRA.
Professor R. Storey (Sheffield, GB)
Slides Video
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal PRO.
Doctor A. Rubboli (Ravenna, IT)
Presentation thumbnail
Low dose of rivaroxaban is a significant achievement for post-MI patients with atherosclerosis. Antiplatelets alone are not enough - Rebuttal CONTRA.
Professor R. Storey (Sheffield, GB)
Presentation thumbnail
All stented patients with atrial fibrillation, stable one year after intervention, should be managed with oral anticoagulants, without antiplatelets - PRO.
Professor R. De Caterina (Pisa, IT)
Slides Video

Access the full session

Session thumbnail
Controversies on anticoagulants post-MI antithrombotic treatment

The Event

Event poster

Acute Cardiovascular Care 2018

3 March 2018 14:40 CET
You may be interested in
thumbnail
Congress Session
Pharmacotherapy in acute coronary syndromes
27 August 2023
thumbnail
Congress Presentation
Risk of bleeding in patients with and without cancer on antiplatelet therapy following myocardial infarction: a study in primary care
25 August 2023
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
26 August 2023
thumbnail
Congress Presentation
Dual pathway inhibition in patients with atherosclerosis with and without heart failure: insights from the XATOA Registry
31 August 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources